Capecitabine – Oral Fluoropyrimidine Carbamate Prodrug Chemotherapy

Capecitabine is an oral, highly selective fluoropyrimidine carbamate that functions as a first-choice systemic cytotoxic prodrug. It is engineered for the targeted chemotherapy of various solid tumors. Capecitabine itself possesses no intrinsic antineoplastic activity; its cytotoxic potential is activated exclusively within the body's tissues through a three-step sequential enzymatic cascade. Following oral administration, the drug is rapidly absorbed in the gastrointestinal tract and undergoes initial hepatic metabolism by carboxylesterase to form 5'-deoxy-5'-fluorocytidine (5'-DFCR). Next, cytidine deaminase, primarily localized in the liver and tumor tissues, converts 5'-DFCR into 5'-deoxy-5'-fluorouridine (5'-DFUR). The final step of metabolic activation is mediated by the enzyme thymidine phosphorylase (dThdPase), which converts 5'-DFUR into the active cytotoxic moiety, 5-fluorouracil (5-FU).

The clinical uniqueness of capecitabine lies in its tumor-selective activation: thymidine phosphorylase expression is significantly higher in malignant cells compared to healthy tissues, generating maximum local 5-FU concentrations directly at the tumor site while minimizing systemic exposure. The mechanism of action of the resulting 5-FU involves two distinct path modalities of tumor suppression. First, its metabolite (FdUMP) covalently binds to thymidylate synthase, completely blocking the synthesis of thymidine triphosphate required for DNA replication. Second, another metabolite (FUTP) erroneously incorporates into cellular RNA structure, disrupting RNA processing and protein synthesis, thereby inducing apoptosis. The drug displays high bioavailability, and its inactive metabolites are predominantly cleared via the kidneys in the urine.

The drug is administered orally. Prior to initiating therapy, screening for dihydropyrimidine dehydrogenase (DPD) expression status or activity is recommended, as inherited DPD deficiency carries a critical risk of severe, life-threatening systemic toxicity. Continuous monitoring of complete blood counts, renal function, and skin integrity is mandatory throughout treatment.

Wikipedia page
Capecitabine

Indications

Capecitabine is indicated as systemic monotherapy or in combination regimens for adult patients with the following malignant solid tumors:

  • Colorectal Cancer: adjuvant treatment of Duke's C (Stage III) colon cancer following surgical resection, and as first-line therapy for patients with metastatic colorectal carcinoma.
  • Breast Cancer: in combination with docetaxel for locally advanced or metastatic breast cancer after failure of anthracycline-containing chemotherapy, or as monotherapy where taxane and anthracycline regimens have failed or are contraindicated.
  • Gastric Cancer: first-line treatment of advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with platinum-based regimens.

Dosage and administration

The dosing regimen of capecitabine is individually calculated based on the patient's body surface area (BSA) and is structured around a cyclic administration schedule.

  • Standard Dose: the recommended monotherapy dose is 1250 mg/m² of body surface area administered orally twice daily (morning and evening; total daily dose of 2500 mg/m²).
  • Schedule and Duration: the drug is administered in conventional 3-week cycles consisting of 14 consecutive days of treatment followed by an obligatory 7-day rest period. The total number of cycles depends on the clinical protocol and tumor response.
  • Administration Method: tablets must be swallowed whole with water within 30 minutes after the completion of a meal (breakfast and dinner). Tablets must not be broken, crushed, or split during handling.
  • Missed Dose: if a scheduled dose is missed, it should not be taken late, and the dose must never be doubled at the next scheduled time. The patient should skip the missed dose and resume their regular schedule.
  • Dose Modification for Toxicity: upon development of Grade 2, 3, or 4 toxicities (such as severe diarrhea or hand-foot syndrome), capecitabine must be withheld until the symptoms resolve to Grade 0–1. Subsequent cycles are resumed with step-down dose reductions of 25% or 50% from the baseline dose.

The use of capecitabine is restricted by severe risks of cumulative toxic liabilities, metabolic incompatibility, and embryofetal harm, and is contraindicated in the following conditions:

  • Hypersensitivity: documented history of allergic reactions, anaphylaxis, or individual hypersensitivity to capecitabine, 5-fluorouracil, or any inactive formulation excipients.
  • Dihydropyrimidine Dehydrogenase Deficiency: known complete absence of DPD enzyme activity, which is responsible for the catabolism and clearance of fluoropyrimidines.
  • Severe Organ Impairment: severe renal insufficiency (creatinine clearance below 30 mL/min) and severe pre-existing hepatic impairment.
  • Pregnancy and Lactation: the drug exhibits direct cytotoxic, mutagenic, and teratogenic properties capable of causing fetal death. Use during pregnancy is strictly contraindicated. Both female and male patients must utilize highly effective contraception during therapy and for 6 months post-treatment. Breastfeeding is prohibited during treatment and for 2 weeks following the final dose.
  • Drug Interactions: concomitant administration with sorivudine or its chemically related analogues (such as brivudine) is strictly contraindicated, as they irreversibly block fluoropyrimidine metabolism, precipitating fatal systemic toxicity.

The side effects of capecitabine are driven by the systemic impact of its active metabolite 5-FU on rapidly dividing healthy epithelial and hematopoietic cell lineages:

  • Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia): a prominent dermatological toxicity presenting as erythema, edema, peeling, painful cracking, and blistering on the palms and soles, necessitating treatment interruption and dose adaptation.
  • Gastrointestinal Toxicities: severe dose-dependent diarrhea (which can lead to critical dehydration and electrolyte imbalances), nausea, vomiting, stomatitis (painful oral mucosal ulcerations), and abdominal pain.
  • Hematologic Disturbances: dose-dependent myelosuppression manifesting as neutropenia (including risks of febrile neutropenia), anemia, thrombocytopenia, and leukopenia.
  • Hepatobiliary System: hyperbilirubinemia (elevated total serum bilirubin levels) and mild to moderate elevations in liver transaminases (ALT, AST).
  • Nervous System and General Symptoms: profound fatigue, asthenia, somnolence, dizziness, taste perversion (dysgeusia), dry eye syndrome, and increased lacrimation.

Frequently Asked Questions

Capecitabine is an oral cytostatic agent that serves as an inactive prodrug. Upon administration, it undergoes a sequential three-step enzymatic conversion. The final activation phase, which transforms it into the cytotoxic compound 5-fluorouracil ($5-FU$), takes place directly within tumor cells via the enzyme thymidine phosphorylase. Because this enzyme is expressed at significantly higher levels in malignant tissues than in healthy ones, capecitabine achieves selective intra-tumor delivery, minimizing systemic toxicity.
Capecitabine is extensively utilized either as a monotherapy or in combination regimens for the treatment of colon and colorectal cancer in both the adjuvant (post-operative) and metastatic settings. It is also indicated for the treatment of advanced or metastatic gastric cancer and advanced or metastatic breast cancer, particularly in patients who have progressed on or are resistant to anthracycline and taxane therapies.
Capecitabine is administered in distinct treatment cycles (most commonly 14 consecutive days of dosing followed by a 7-day rest period). The tablets must be taken strictly within 30 minutes after completing a meal (breakfast and dinner) and swallowed whole with water. Taking the medication on an empty stomach or too long after a meal impairs its absorption profile and can significantly exacerbate gastrointestinal adverse reactions.
Hand-foot syndrome (palmar-plantar erythrodysesthesia) is a hallmark class-effect of capecitabine. Symptoms manifest as redness, severe dryness, peeling, tingling, and, in advanced stages, painful swelling, blistering, or fissures on the palms and soles. Patients are advised to apply thick emollient creams daily, avoid hot water exposure, minimize friction or prolonged pressure on hands and feet, and wear loose-fitting footwear. If significant pain or skin breakdown occurs, the physician will temporarily withhold therapy.
Capecitabine can cause severe enterotoxicities. Patients must immediately hold their scheduled doses and contact their oncologist upon experiencing severe diarrhea (an increase of 4 or more loose stools per day compared to baseline), frequent vomiting (more than twice within a 24-hour window), intractable nausea, or severe stomatitis (painful oral ulcerations that interfere with eating or drinking). Pausing treatment promptly for these toxicities is critical to prevent life-threatening dehydration.

List of medicines by active substance

-22%
Capixet
View
Everest

Capixet

Capecitabine
500 mg 14 tablets
7107₴ 9119₴
✅ All products loaded (1)
Unifarm

Unifarm app

Safari → Share → Add to Home Screen Firefox: menu ⋮ → Install or Add to Home screen. If missing, open the site in Chrome. Chrome: menu ⋮ → Install app or Add to Home screen.

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00